OR
ORKA.US Oruka Therapeutics, Inc.
- Market cap
- USD 6.73B
- P/E
- -
- P/B
- 5.98x
- ROE
- -13.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ORKA.US undervalued?
Graham numberThe Graham number of Oruka Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oruka Therapeutics, Inc. fundamental analysis
No fundamental analysis for Oruka Therapeutics, Inc. yet.
Oruka Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, an…
Full company profileOruka Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oruka Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 |
| Gross Profit | -24.0K | -27.0K | -22.0K | -89.0K | -93.0K | -91.0K | -114K | -111K | -27.0K | -83.0K | -180K |
| Operating Income | -16.6M | -18.7M | -8.12M | -5.81M | -9.77M | -19.3M | -9.84M | -7.30M | -88.1M | -122M | -198M |
| EBITDA | -16.4M | -18.5M | -7.94M | -5.55M | -9.65M | -19.2M | -9.81M | -5.23M | -82.2M | -105M | -192M |
| Net Income | -16.4M | -18.5M | -7.93M | -5.48M | -9.74M | -19.3M | -9.93M | -5.34M | -83.7M | -105M | -164M |
| EPS | -392 | -383 | -124 | -50 | -2.07 | -1.39 | -0.69 | -0.37 | -4.99 | -2.31 | -2.29 |
| Balance Sheet | |||||||||||
| Total Assets | 24.6M | 12.4M | 6.83M | 8.54M | 50.4M | 54.9M | 43.1M | 37.9M | 396M | 489M | 1.23B |
| Total Liabilities | 2.44M | 2.09M | 793K | 926K | 3.91M | 3.88M | 1.41M | 841K | 13.8M | 16.7M | 33.9M |
| Shareholders' Equity | 22.2M | 10.3M | 6.03M | 7.61M | 46.5M | 51.0M | 41.7M | 37.0M | 382M | 472M | 1.20B |
| Cash & Short-term Investments | 21.2M | 11.8M | 6.61M | 8.36M | 49.1M | 53.4M | 42.4M | 37.4M | 376M | 337M | 920M |
| Total Debt | - | - | - | 25.0K | 450K | 483K | 383K | 280K | 968K | 1.93M | 2.93M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -15.0M | -17.5M | -8.24M | -4.80M | -7.73M | -18.8M | -10.9M | - | -57.8M | -88.2M | -135M |
| Capital Expenditure | 12.0K | 3.00K | 4.00K | 4.00K | 19.0K | 43.0K | 2.00K | - | 189K | 209K | 208K |
| Free Cash Flow | -15.0M | -17.5M | -8.25M | -4.81M | -7.74M | -18.8M | -10.9M | - | -58.0M | -88.4M | -135M |
| Ratios | |||||||||||
| ROE | -74.1% | -180.0% | -131.5% | -72.0% | -20.9% | -37.9% | -23.8% | -14.4% | -21.9% | -22.3% | -13.7% |
| ROA | -66.8% | -149.5% | -116.2% | -64.2% | -19.3% | -35.2% | -23.0% | -14.1% | -21.1% | -21.6% | -13.3% |
| Debt to Equity | - | - | - | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Oruka Therapeutics, Inc. dividends
Oruka Therapeutics, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:12 on Sep 3, 2024.
Who owns Oruka Therapeutics, Inc.
- Insiders 1.62%
- Institutions 98.39%
- Public & others 0.00%
- Shares outstanding 67.8M
- Free float 58.6M
Top funds holding ORKA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.90M | 2.80% | +9.95% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.73M | 2.55% | +2.68% | Oct 2026 |
| American Funds SMALLCAP World A | 1.53M | 2.25% | 0.00% | Sep 2026 |
| American Funds New Economy A | 1.32M | 1.95% | 0.00% | Sep 2026 |
| Fidelity Growth Company Fund | 1.29M | 1.91% | 0.00% | Aug 2026 |
| iShares Russell 2000 ETF | 1.28M | 1.88% | 0.00% | Oct 2026 |
| Polar Capital Biotech S Inc | 1.16M | 1.72% | 0.00% | Sep 2026 |
| Fidelity Select Health Care | 880K | 1.30% | +1.73% | Aug 2026 |
| Fidelity Advisor Biotechnology I | 737K | 1.09% | 0.00% | Sep 2026 |
| Vanguard Small Cap Index | 670K | 0.99% | +3,519.01% | Sep 2026 |
| Fidelity Small Cap Growth | 654K | 0.96% | -4.64% | Aug 2026 |
| Fidelity Select Biotechnology | 563K | 0.83% | 0.00% | Aug 2026 |
| Fidelity Small Cap Index | 552K | 0.81% | +0.15% | Aug 2026 |
| Franklin Biotechnology Discv A(acc)USD | 548K | 0.81% | 0.00% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 528K | 0.78% | +46.75% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 472K | 0.70% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 457K | 0.67% | -0.45% | Oct 2026 |
| T. Rowe Price Mid-Cap Growth | 447K | 0.66% | 0.00% | Sep 2026 |
| Fidelity Advisor Health Care I | 428K | 0.63% | 0.00% | Sep 2026 |
| Harbor Small Cap Growth Instl | 418K | 0.62% | +34.55% | Sep 2026 |
Top institutions holding ORKA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 9.06M | 13.36% | +21.88% | Jun 2026 |
| BlackRock Inc | 4.99M | 7.36% | +41.48% | Jun 2026 |
| VR Adviser, LLC | 4.15M | 6.12% | 0.00% | Jun 2026 |
| Fairmount Funds Management LLC | 3.71M | 5.46% | 0.00% | Jun 2026 |
| Capital World Investors | 3.40M | 5.02% | 0.00% | Jun 2026 |
| RTW INVESTMENTS, LLC | 3.14M | 4.63% | +52.52% | Jun 2026 |
| State Street Corp | 2.67M | 3.94% | +65.67% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.36M | 3.48% | +26.96% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 2.14M | 3.16% | -7.58% | Jun 2026 |
| Deep Track Capital, LP | 1.93M | 2.84% | -5.32% | Jun 2026 |
| Bellevue Group AG | 1.66M | 2.44% | +226.86% | Jun 2026 |
| Franklin Templeton Inc | 1.62M | 2.39% | +61.49% | Jun 2026 |
| Remedium Capital Partners, LLC | 1.57M | 2.31% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 1.55M | 2.29% | 0.00% | Jun 2026 |
| Viking Global Investors LP | 1.50M | 2.22% | -43.62% | Jun 2026 |
| Geode Capital Management, LLC | 1.43M | 2.11% | +49.75% | Jun 2026 |
| Jupiter Topco LLC | 1.38M | 2.03% | 0.00% | Jun 2026 |
| Perceptive Advisors LLC | 1.35M | 1.98% | -3.61% | Jun 2026 |
| Polar Capital Holdings PLC | 1.23M | 1.81% | +17.27% | Jun 2026 |
| Citadel Advisors Llc | 1.12M | 1.65% | +11.06% | Jun 2026 |
Oruka Therapeutics, Inc. company profile
- Company name
- Oruka Therapeutics, Inc.
- Ticker
- ORKA.US
- Exchange
- USA Stocks
- Listed since
- Aug 8, 1997
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 68
- Fiscal year end
- December
- Address
- 855 Oak Grove Avenue, Menlo Park, CA, United States, 94025
- Phone
- 650 606 7910
- Website
- orukatx.com
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Oruka Therapeutics, Inc. management
9- Dr. Lawrence Otto Klein Ph.D.President, CEO & Director · born 1983
- Mr. Paul T. QuinlanGeneral Counsel & Secretary · born 1963
- Dr. Joana Goncalves M.D.Chief Medical Officer · born 1974
- Mr. Arjun Agarwal CPASenior VP of Finance & Treasurer · born 1976
- Ms. Laura SandlerChief Operating Officer · born 1977
- Mr. Alan LadaVP of IR & Capital Markets
- Mr. Christopher FinchSenior VP and Head of Business Development & Strategy
- Dr. Rajiv PanwarSenior VP and Head of Chemistry, Manufacturing & Controls
- Mr. Larry Todd EdwardsChief Commercial Officer · born 1963